As I've said, on the impact of CETA on drug pricing, this agreement has been carefully structured so that the full impact is not felt for a full eight years.
As I think we are all aware, this is a very fast-moving space, particularly when it comes to new developments, when it comes to issues of biologics, when it comes to the trade-off between generic and brand name drugs. Our response to CETA very much needs to be, and will be, embedded in broader work that my colleague, the Minister of Health, is doing on—